Treatment
Management
of psychological factors affecting the patient’s med-ical condition should be
tailored both to the particular psycholog-ical factor of relevance and to the
medical outcome of concern. Some general guidelines, however, can be helpful.
The physician, whether in primary care or a specialty, should not ignore
appar-ent psychiatric illness. Unfortunately, this occurs all too often because
of discomfort, stigma, lack of training, or disinterest. Referring the patient
to a mental health specialist for evaluation is certainly better than ignoring
the psychological problem but should not be regarded as “disposing” of it,
because the physician must still attend to its potential impact on the
patient’s medical illness. Similarly, psychiatrists and other mental health
practitio-ners should not ignore coincident medical disease and should not
assume that referral to a nonpsychiatric physician absolves them of all
responsibility for the patient’s medical problem.
If the
patient has a treatable Axis I disorder, treatment for it should be provided.
Whereas this is obviously justified on the basis of providing relief from the
Axis I disorder, psychiatric treatment is further supported by the myriad ways
in which the psychiatric disorder may currently or in future adversely affect
the medical illness. The same psychopharmacological and psy-chotherapeutic treatments
used for Axis I mental disorders are normally appropriate when an affected
medical condition is also present. However, even well-established psychiatric
treatments supported by randomized controlled trials have seldom been validated
in the medically ill, who are typically excluded from the controlled trials.
Thus, psychiatric treatments may not always be directly generalizable to, and
often must be modified for, the medically ill.
When
prescribing psychiatric medications for patients with significant medical
comorbidity, the psychiatrist should keep in mind potential adverse effects on
impaired organ systems (e.g., anticholinergic exacerbation of postoperative
ileus; tricyclic antidepressant causing completion of heart block), changes in
pharmacokinetics (absorption, protein binding, metabolism and excretion) and
drug–drug interactions. Psychotherapy may also require modification in patients
with comorbid medical illness, including greater flexibility regarding the
length and frequency of appointments, and deviations from standard therapeutic
ab-stinence and neutrality. Psychotherapists treating patients with PFAMC
should usually be much more active in communicating with other health care
professionals caring for the patient (with the patient’s consent) than is
usually the case in psychotherapy.
If the
patient has an Axis II personality disorder or other prominent personality or
coping style, the psychiatrist should modify the patient’s treatment
accordingly, which is usually more easily accomplished than trying to change
the patient’s personality. For example, patients who tend to be paranoid or
mistrustful should receive more careful explanations, particu-larly before
invasive or anxiety-provoking procedures. With nar-cissistic patients, the
psychiatrist should avoid relating in ways that may seem excessively
paternalistic or authoritarian to the patient. With some dependent patients, it
may be advisable to be more directive, without overdoing it and fostering
excessive dependency.
In some
instances, psychiatric symptoms not meeting the thresh-old for an Axis I
diagnosis will respond positively to the same treatments used for the analogous
Axis I psychiatric disorder, with appropriate modifications as noted before.
There is not a great amount of treatment research on subsyndromal psychiatric
symptoms, and even less in patients with comorbid medical ill-ness, so this
area of practice remains less evidence-based. Some psychiatric symptoms affecting
a medical condition may be ame-nable to stress management and other behavioral
techniques as well as appropriate reassurance.
Any
intervention directed by the psychiatrist at a par-ticular patient’s
psychological symptoms or behavior should be grounded in exploratory discussion
with the patient. Interven-tions without such grounding tend to seem at best
superficial and artificial and at worst are entirely off the mark. For example,
if the psychiatrist wrongly presumes to know why a particular patient seems
anxious without asking, the patient is likely to feel misunderstood. Facile,
nonspecific reassurance can undermine the physician–patient relationship
because the patient is likely to feel that the psychiatrist is out of touch
with and not really interested in the patient’s experience. It is especially
important with depressed patients that psychiatrists avoid premature or
unrealistic reassurance or an overly cheerful attitude; this tends to alienate
depressed patients, who feel that their psychiatrist is insensitive and either
does not understand or does not want to hear about their sadness. Physicians should provide specific and realistic
reassurance, emphasize on a constructive treatment plan and mobilize the
patient’s support system.
As with
Axis II disorders affecting a medical condition, psychia-trists should be aware
of the personality style’s effects on the phy-sician–patient relationship and
modify management better to fit the patient. For example, with type A “time
urgent” patients, psy-chiatrists may need to be more sensitive to issues of
appointment scheduling and waiting times. Group therapy interventions can
enhance active coping with serious medical illnesses like can-cer, heart
disease and renal failure but to date have usually been designed to be broadly
generalizable rather than targeted to one particular trait or style (with the
exception of type A behavior).
Another
general guideline is not to attack or interfere with a patient’s defensive
style unless the defense is having an adverse impact on the medical illness or
its management. Psychiatrists are particularly tempted to intervene when the
defense is dramatic, breaks with reality, or makes the psychiatrist uncomfortable.
For
example, denial is a defense mechanism that reduces anxiety and conflict by
blocking conscious awareness of thoughts, feelings, or facts that an individual
cannot face. Denial is com-mon in the medically ill but varies in its timing,
strength and adaptive value. Some patients are aware of what is wrong with them
but consciously suppress this knowledge by avoiding think-ing about or
discussing it. Others cope with the threat of being overwhelmed by their
illness by unconsciously repressing it and thereby remain unaware of their
illness. Marked denial, in which the patient emphatically refuses to accept the
existence or sig-nificance of obvious symptoms and signs of the disease, may be
seen by the psychiatrist as an indication that the patient is “crazy” because
the patient seems impervious to rational persuasion. In the absence of signs of
another major psychiatric disorder (e.g., paranoid delusions), such denial is
not often a sign of psychosis but rather represents a defense against overwhelming
fear.
The adaptive value of denial may vary, depending on the nature or stage of illness. When a patient’s denial does not preclude cooperation with treatment, the psychiatrist should leave it alone. The psychiatrist does have an ethical and professional obligation to ensure that the patient has been informed about the illness and treatment. After that, if the patient accepts treatment but persists with an irrationally optimistic outlook, the psychiatrist should re-spect the patient’s need to use denial to cope. For some, the denial is fragile, and the psychiatrist must decide whether the defense should be supported and strengthened, or if the patient had better give up the denial to discuss fears directly and receive reassur-ance from the psychiatrist. The psychiatrist should not support denial by giving the patient false information, but rather encour-age hope and optimism. When denial is extreme, patients may refuse vital treatment or threaten to leave against medical advice. Here, the psychiatrist must try to help reduce denial but not bydirectly assaulting the patient’s defenses. Because such desper-ate denial of reality usually reflects intense underlying anxiety, trying to scare the patient into cooperation will intensify denial and the impulse to flight. A better strategy for the psychiatrist is to avoid directly challenging the patient’s claims while simulta-neously reinforcing concern for the patient and maximizing the patient’s sense of control.
This is
an area of research with many promising approaches. To achieve smoking
cessation, bupropion, nicotine replace-ment, behavioral therapies and other
pharmacological strate-gies all warrant consideration. Behavioral strategies
are also useful in promoting better dietary practices, sleep hygiene, safe sex
and exercise. For some patients, change can be achieved ef-ficiently through
support groups, whereas others change more effectively through a one-to-one relationship
with a health care professional.
Biofeedback,
relaxation techniques, hypnosis and other stress management interventions have
been helpful in reducing stress-induced exacerbations of medical illness
including cardiac, gas-trointestinal, headache and other symptoms.
Pharmacological in-terventions have also been useful (e.g., the widespread
practice of prescribing benzodiazepines during acute myocardial infarction to
prevent stress-induced increase in myocardial work).
The
primary focus is on those effects for which there is reasonable evidence from
controlled studies. Space considerations preclude inclusion of all valuable studies
and all medical disorders.
Most of
the early research suffers from serious method-ological flaws, including use of
small biased samples, limited or no statistical analysis, poor (if any)
controls and retrospective designs subject to recall and other biases. This
early work gener-ated excitement and interest in psychosomatic medicine but
also produced ideas that in retrospect were intellectually appealing but
erroneous and simplistic regarding the special designation of certain diseases
as psychosomatic.
Later
research has shown improvements in methodology, but problems in design and
interpretation continue. Several stud-ies that seem to show significant effects
of psychological factors on medical disease are inconclusive because of
nonequivalence in groups at baseline either in medical disease severity or in
treat-ments received (many studies do not even monitor this possibil-ity). Some
studies fail to attend to important potential confound-ing factors such as
smoking or diet. A number of studies measure too many psychological variables
and then overly emphasize the few “discovered” positive associations in the
published results. Failure to standardize measures of initial psychological
factors and measures of medical outcome has also been frequent. Despite these
and other critiques, a large and growing body of disease-specific research is
illuminating the full range of PFAMC.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.